Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Axogen, Inc.
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 24, 2025
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. To Host Analyst & Investor Day on March 4th
February 25, 2025
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
February 25, 2025
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
February 11, 2025
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2025
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
January 10, 2025
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
November 07, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
October 24, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
September 06, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
September 03, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. Announces New Leadership Appointments
August 08, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 23, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
July 01, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
June 24, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
May 28, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
May 16, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
May 14, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc Reports First Quarter 2024 Financial Results
May 02, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
April 29, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
April 16, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
March 05, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
February 13, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
January 18, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
January 04, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
January 04, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen Announces Promotions on Research and Development Team
January 04, 2024
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AXGN
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
December 26, 2023
From
Axogen, Inc.
Via
GlobeNewswire
Tickers
AMWL
AXGN
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.